Nanotechnology in Pharmaceutical Manufacturing

Pharmaceutical Manufacturing Handbook: Production and Processes

Volumn , Issue , 2007, Pages 1249-1288

  Jin, Yiguang ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Drug delivery nanotechnology; High pressure homogenization (HPH); Pharmaceutical manufacturing nanotechnology

Indexed keywords

EID: 58949104134     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470259818.ch32     Document Type: Chapter

References (147)

1. Silva, G. A. (2006), Neuroscience nanotechnology: Progress, opportunities and challenges, Nat. Rev. Neurosci., 7, 65-74.
2. Wang, Z. L. (2000), Characteriaztion of Nanophase Materials, Wiley-VCH, Weinheim, Germany, pp. 1-6.
3. Vasir, J. K., Reddy, M. K., and Labhasetwar, V. D. (2005), Nanosystems in drug targeting: Opportunities and challenges, Curr. Nanosci., 1, 47-64.
4. Lane, N. F. (2004), in Bhushan, B., Ed., Springer Handbook of Nanotechnology, Springer-Verlag, Berlin.
5. Goodsell, D. S. (2004), Bionanotechnology: Lessons from Nature, Wiley-Liss, Hoboken, NJ, pp. 1-6.
6. Fritz, J., Baller, M. K., Lang, H. P., Rothuizen, H., Vettiger, P., Meyer, E., Guntherodt, H. J., Gerber, C., and Gimzewski, J. K. (2000), Translating biomolecular recognition into nanomechanics, Science, 288, 316-318.
7. Xu, X. H. N., Chen, J., Jeffers, R. B., and Kyriacou, S. (2002), Direct measurement of sizes and dynamics of single living membrane transporters using nanooptics, Nano Lett., 2, 175-182.
8. Li, J., Papadopoulos, C., and Xu, J. (1999), Nanoelectronics - Growing Y-junction carbon nanotubes, Nature, 402, 253-254.
9. Sergeev, G. B. (2006), Nanochemistry, Elsevier, Amsterdam, The Netherlands.
10. Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2005), Nanomedicine: Current status and future prospects, FASEB J., 19, 311-330.
11. Whitesides, G. M. (2003), The " right " size in nanobiotechnology, Nat. Biotechnol., 21, 1161-1165.
12. Lee, K. B., Park, S. J., Mirkin, C. A., Smith, J. C., and Mrksich, M. (2002), Protein nanoarrays generated by dip-pen nanolithography, Science, 295, 1702-1705.
13. Liu, G. Y., and Amro, N. A. (2002), Positioning protein molecules on surfaces: A nanoengineering approach to supramolecular chemistry, Proc. Nat. Acad. Sci. U.S.A., 99, 5165-5170.
14. Quake, S. R., and Scherer, A. (2000), From micro-to nanofabrication with soft materials, Science, 290, 1536-1540.
15. Xia, Y. N., McClelland, J. J., Gupta, R., Qin, D., Zhao, X. M., Sohn, L. L., Celotta, R. J., and Whitesides, G. M. (1997), Replica molding using polymeric materials: A practical step toward nanomanufacturing, Adv. Mater., 9, 147-149.
16. http://www.whitehouse.gov/omb/budget/fy2007/nsf.html 2007-1-5.
17. Service, R. F. (2005), Nanotechnology takes aim at cancer, Science, 310, 1132-1134.
18. Vauthey, S., Santoso, S., Gong, H., Watson, N., and Zhang, S. (2002), Molecular self-assembly of surfactant-like peptides to form nanotubes and nanovesicles, Proc. Nat. Acad. Sci. U. S. A., 99, 5355-5360.
19. Rabinow, B. E. (2004), Nanosuspensions in drug delivery, Nat. Rev. Drug Discov., 3, 1-12.
20. Vinogradov, S. V. (2006), Colloidal microgels in drug delivery applications, Curr. Pharm. Des., 12, 4703-4712.
21. Jin, Y., Qiao, Y., Li, M., Ai, P., and Hou, X. (2005), Langmuir monolayers of the long-chain alkyl derivatives of a nucleoside analogue and the formation of self-assembled nanoparticles, Coll. Surf. B: Biointerf., 42, 45-51.
22. Jin, Y., Tong, L., Ai, P., Li, M., and Hou, X. (2006), Self-assembled drug delivery systems. 1. Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles (SAN), Int. J. Pharm., 309, 199-207.
23. Boas, U., and Heegaard, P. M. H. (2004), Dendrimers in drug research, Chem. Soc. Rev., 33, 43-63.
24. Kroto, H. W., Heath, J. R., O'Brien, S.C., Curl, R. F., and Smalley, R. E. (1985), Nature, 318, 162-163.
25. Satoh, M., and Takayanagi, I. (2006), Pharmacological studies on fullerene (C60), a novel carbon allotrope, and its derivatives, J. Pharm. Sci., 100, 513-518.
26. Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., and Weiss, S. (2005), Quantum dots for live cells, in vivo imaging, and diagnostics, Science, 307, 538-544.
27. Muller, R. H., Mader, K., and Gohla, S. (2000), Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art, Eur. J. Pharm. Biopharm., 50, 161-177.
28. Groneberg, D. A., Giersig, M., Welte, T., and Pison, U. (2006), Nanoparticle-based diagnosis and therapy, Curr. Drug Targets, 7, 643-648.
29. Couvreur, P., Barratt, G., Fattal, E., Legrand, P., and Vauthier, C. (2002), Nanocapsule technology: A review, Crit. Rev. Ther. Drug Carrier Syst., 19, 99-134.
30. Barenholz, Y. (2001), Liposome application: Problems and prospects, Curr. Opin. Coll. Interf. Sci., 6, 66-77.
31. Torchilin, V. P. (2005), Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145-160.
32. Uchegbu, I. F., and Vyas, S. P. (1998), Non-ionic surfactant based vesicles (niosomes) in drug delivery, Int. J. Pharm., 172, 33-70.
33. Sadurni, N., Solans, C., Azemara, N., and Garcia-Celma, M. J. (2005), Studies on the formation of O/W nano-emulsions, by low-energy emulsification methods, suitable for pharmaceutical applications, Eur. J. Pharm. Sci., 26, 438-445.
34. Solans, C., Izquierdo, P., Nolla, J., Azemara, N., and Garcia-Celma, M. J. (2005), Nano-emulsions, Curr. Opin. Coll. Interf. Sci., 10, 102-110.
35. Jones, M.-C., and Leroux, J.-C. (1999), Polymeric micelles - A new generation of colloidal drug carriers, Eur. J. Pharm. Biopharm., 48, 101-111.
36. Torchilin, V. P. (2007), Micellar nanocarriers: Pharmaceutical perspectives, Pharm. Res., 24, 1-16.
37. Bianco, A., Kostarelos, K., and Prato, M. (2005), Applications of carbon nanotubes in drug delivery, Curr. Opin. Chem. Biol., 9, 674-679.
38. Foley, S., Crowley, C., Smaihi, M., Bonfils, C., Erlanger, B. F., Seta, P., and Larroqueb, C. (2002), Cellular localisation of a water-soluble fullerene derivative, Biochem. Biophys. Res. Commun., 294, 116-119.
39. Tsao, N., Luh, T.-Y., Chou, C.-K., Chang, T.-Y., Wu, J.-J., Liu, C.-C., and Lei, H.-Y. (2002), In vitro action of carboxyfullene, J. Antimicrob. Chemother., 49, 641-649.
40. Ozkan, M. (2004), Quantum dots and other nanoparticles: What can they offer to drug discovery, Drug Discov. Today, 9, 1065-1071.
41. Oberdorster, G., Oberdorster, E., and Oberdorster, J. (2005), Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles, Environ. Health Perspect., 113, 823-839.
42. des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., and Preat, V. (2006), Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach, J. Controlled Release, 116, 1-27.
43. Lemos-Senna, E., Wouessidjewe, D., Lesieur, S., and Duchene, D. (1998), Preparation of amphiphilic cyclodextrin nanospheres using the emulsification solvent evaporation method. Influence of the surfactant on preparation and hydrophobic drug loading, Int. J. Pharm., 170, 119-128.
44. Xiao, S., Tong, C., Liu, X., Yu, D., Liu, Q., Xue, C., Tang, D., and Zhao, L. (2006), Preparation of folate-conjugated starch nanoparticles and its application to tumor-targeted drug delivery vector, Chin. Sci. Bull., 51, 1693-1697.
45. Sokolova, V. V., Radtke, I., Heumann, R., and Epple, M. (2006), Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles, Biomaterials, 27, 3147-3153.
46. Ueno, Y., Futagawa, H., Takagi, Y., Ueno, A., and Mizushima, Y. (2005), Drug-incorporating calcium carbonate nanoparticles for a new delivery system, J. Controlled Release, 103, 93-98.
47. Souza, G., Christianson, D. R., Staquicini, F. I., Ozawa, M. G., Snyder, E. Y., Sidman, R. L., Miller, J. R., Arap, W., and Pasqualini, R. (2006), Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents, Proc. Nat. Acad. Sci. U.S.A., 103, 1215-1220.
48. Guinebretiere, S., Briancon, S., Lieto, J., Mayer, C., and Fessi, H. (2002), S tudy of the emulsion-diffusion of solvent: Preparation and characterization of nanocapsules, Drug Dev. Res., 57, 18-33.
49. Hillaireau, H., Doan, T. L., Appel, M., and Couvreur, P. (2006), Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages, J. Controlled Release, 116, 346-352.
50. New, R. R. C. (1990), Liposomes: A Practical Approach, Oxford University Press, Oxford, pp. 1-162.
51. Vinogradov, S., Batrakova, E., and Kabanov, A. (1999), Poly(ethylene glycol)-polyethylenimine NanoGel particles: Novel drug delivery systems for antisense oligonucleotides, Coll. Surf. B: Biointerf., 16, 291-304.
52. Vinogradov, S. V., Kohli, E., and Zeman, A. D. (2005), Cross-linked polymeric nanogel formulations of 5 '-triphosphates of nucleoside analogues: Role of the cellular membrane in drug release, Mol. Pharm., 2, 449-461.
53. Bosman, A. W., Janssen, H. M., and Meijer, E. W. (1999), About dendrimers: Structure, physical properties, and applications, Chem. Rev., 99, 1665-1688.
54. Gagner, J., Johnson, H., Watkins, E., Li, Q., Terrones, M., and Majewski, J. (2006), Carbon nanotube supported single phospholipid bilayer, Langmuir, 22, 10909-10911.
55. Kam, N. W. S., Liu, Z., and Dai, H. (2006), Carbon nanotubes as intracellular transporters for proteins and DNA: An investigation of the uptake mechanism and pathway, Ang. Chem. Int. Ed., 45, 577-581.
56. Zakharian, T. Y., Seryshev, A., Sitharaman, B., Gilbert, B. E., Knight, V., and Wilson, L. J. (2005), A fullerene-paclitaxel chemotherapeutic: Synthesis, characterization, and study of biological activity in tissue culture, J. Am. Chem. Soc., 127, 12508-12509.
57. Akerman, M. E., Chan, W. C. W., Laakkonen, P., Bhatia, S. N., and Ruoslahti, E. (2002), Nanocrystal targeting in vivo, Proc. Nat. Acad. Sci. U.S.A., 99, 12617-12621.
58. Boulmedais, F., Bauchat, P., Brienne, M. J., Arnal, I., Artzner, F., Gacoin, T., Dahan, M., and Marchi-Artzner, V. (2006), Water-soluble pegylated quantum dots: From a composite hexagonal phase to isolated micelles, Langmuir, 22, 9797-9803.
59. Algar, W. R., and Krull, U. J. (2006), Adsorption and hybridization of oligonucleotides on mercaptoacetic acid-capped CdSe/ZnS quantum dots and quantum dot-oligonucleotide conjugates, Langmuir, 22, 11346-11352.
60. Matteucci, M. E., Hotze, M. A., Johnston, K. P., and Williams, III. R. O. (2006), Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization, Langmuir, 22, 8951-8959.
61. Douroumis, D., and Fahr, A. (2006), Nano-and micro-particulate formulations of poorly water-soluble drugs by using a novel optimized technique, Eur. J. Pharm. Biopharm., 63, 173-175.
62. Torchilin, V. P. (2006), Multifunctional nanocarriers, Adv. Drug Deliv. Rev., 58, 1532-1555.
63. Banham, A. D., Standish, M. M., and Watkins, J. C. (1965), Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol., 13, 238-252.
64. Lasic, D. D., Joannic, R., Keller, B. C., Frederik, P. M., and Auvray, L. (2001), Spontaneous vesiculation, Adv. Coll. Interf. Sci., 89-90, 337-349.
65. Bhalerao, S. S., and Harshal, A. R. (2003), Preparation, optimization, characterization, and stability studies of salicylic acid liposomes, Drug Dev. Ind. Pharm., 29, 451-467.
66. Szoka, F., and Papahadjopoulos, D. (1978), Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation, Proc. Nat. Acad. Sci. U. S. A., 75, 4194-4198.
67. Pons, M., Foradada, M., and Estelrich, J. (1993), Liposomes obtained by the ethanol injection method, Int. J. Pharm., 95, 51-56.
68. Kikuchi, H., Yamauchi, H., and Hirota, S. A. (1994), Polyol dilution method for mass production of liposomes, J. Liposome Res., 4, 71-91.
69. Wang, T., Deng, Y., Geng, Y., Gao, Z., Zou, J., and Wang, Z. (2006), Preparation of submicron unilamellar liposomes by freeze-drying double emulsions, Biochim. Biophys. Acta, 1758, 222-231.
70. Ning, M.-Y., Guo, Y.-Z., Pan, H.-Z., Yu, H.-M., and Gu, Z.-W. (2005), Preparation and evaluation of proliposomes containing clotrimazole, Chem. Pharm. Bull., 53, 620-624.
71. Barnadas-Rodriguez, R., and Sabes, M. (2001), Factors involved in the production of liposomes with a high-pressure homogenizer, Int. J. Pharm., 213, 175-186.
72. Taira, M. C., Chiaramoni, N. S., Pecuch, K. M., and Alonso-Romanowski, S. (2004), Stability of liposomal formulations in physiological conditions for oral drug delivery, Drug Deliv., 11, 123-128.
73. Glavas-Dodov, M., Fredro-Kumbaradzi, E., Goracinova, K., Simonoska, M., Calis, S., Trajkovic-Jolevska, S., and Hincal, A. A. (2005), The effects of lyophilization on the stability of liposomes containing 5-FU, Int. J. Pharm., 291, 79-86.
74. Liang, W., Levchenko, T. S., and Torchilin, V. P. (2004), Encapsulation of ATP into liposomes by different methods: Optimization of the procedure, J. Microencapsul., 21, 251-261.
75. Haran, G., Cohen, R., Bar, L. K., and Barenholz, Y. (1993), Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta, 1151, 201-215.
76. Zhigaltsev, I. V., Kaplun, A. P., Kucheryanu, V. G., Kryzhanovsky, G. N., Kolomeichuk, S. N., Shvets, V. I., and Yurasov, V. V. (2001), Liposomes containing dopamine entrapped in response to transmembrane ammonium sulfate gradient as carrier system for dopamine delivery into the brain of parkinsonian mice, J. Liposome Res., 11, 55-71.
77. Hwang, S. H., Maitani, Y., Qi, X. R., Takayama, K., and Nagai, T. (1999), R emote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods, Int. J. Pharm., 179, 85-95.
78. Abraham, S. A., Edwards, K., Karlsson, G., Hudon, N., Mayer, L. D., and Bally, M. B. (2004), An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes, J. Controlled Release, 96, 449-461.
79. Gulati, M., Grover, M., Singh, S., and Singh, M. (1998), Lipophilic drug derivatives in liposomes, Int. J. Pharm., 165, 129-168.
80. Wagner, A., Vorauer-Uhl, K., and Katinger, H. (2002), Liposomes produced in a pilot scale: Production, purification and efficiency aspects, Eur. J. Pharm. and Biopharm., 54, 213-219.
81. Wagner, A., Vorauer-Uhl, K., Kreismayr, G., and Katinger, H. (2002), The crossflow injection technique - An improvement of the ethanol injection method, J. Liposome Res., 12, 259-270.
82. Wagner, A., Platzgummer, M., Kreismayr, G., Quendler, H., Stiegler, G., Ferko, B., Vecera, G., Vorauer-Uhl, K., and Katinger, H. (2006), GMP production of liposomes: A new industrial approach, J. Liposome Res., 16, 311-319.
83. Woodle, M. C., and Scaria, P. (2001), Cationic liposomes and nucleic acids, Curr. Opin. Coll. Interf. Sci., 6, 78-84.
84. Templeton, N. S. (2002), Cationic liposome-mediated gene delivery in vivo, Biosci. Rep., 22, 283-295.
85. Ishida, T., Harashima, H., and Kiwada, H. (2002), Liposome clearance, Biosci. Rep., 22, 197-224.
86. Winterhalter, M., Frederik, P. M., Vallner, J. J., and Lasic, D. D. (1997), Stealth ® liposomes: From theory to product, Adv. Drug Deliv. Rev., 24, 165-177.
87. Ishida, T., Ichihara, M., Wang, X., and Kiwada, H. (2006), Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes, J. Controlled Release, 115, 243-250.
88. Moghimi, S. M., Hamad, I., Andresen, T. L., Jorgensen, K., and Szebeni, J. (2006), Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production, FASEB J., 20, 2591-2593.
89. Drummond, D. C., Zignani, M., and Leroux, J.-C. (2000), Current status of pH-sensitive liposomes in drug delivery, Prog. Lipid Res., 39, 409-460.
90. Yatvin, M. B., Weinstein, J. N., Dennis, W. H., and Blumenthal, R. (1978), Liposomes and local hyperthermia: Selective delivery of methotrexate to heated tumors, Science, 202, 1290-1293.
91. Kono, K. (2001), Thermosensitive polymer-modified liposomes, Adv. Drug Deliv. Rev., 53, 307-319.
92. Zhang, J. Q., Zhang, Z. R., Yang, H., Tan, Q. Y., Qin, S. R., and Qiu, X. L. (2005), Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: In vitro and in vivo studies, Pharm. Res., 22, 573-583.
93. Koning, G. A., Kamps, J. A. A. M., and Scherphof, G. L. S. (2002), Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes, Cancer Detection Prevention, 26, 299-307.
94. Mehnert, W., and Mader, K. (2001), Solid lipid nanoparticles: Production, characterization and applications, Adv. Drug Deliv. Rev., 47, 165-196.
95. Shive, M. S., and Anderson, J. M. (1997), Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 28, 5-24.
96. Sommerfeld, P., Schroeder, U., and Sabel, B. A. (1997), Long-term stability of PBCA nanoparticle suspensions suggests clinical usefulness, Int. J. Pharm., 155, 201-207.
97. Sommerfeld, P., Schroeder, U., and Sabel, B. A. (1998), Sterilization of unloaded polybutylcyanoacrylate nanoparticles, Int. J. Pharm., 164, 113-118.
98. Chorny, M., Fishbein, I., Danenberg, H. D., and Golomb, G. (2002), Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetics, J. Controlled Release, 83, 389-400.
99. Govender, T., Stolnik, S., Garnett, M. C., Illum, L., and Davis, S. S. (1999), PLGA nanoparticles prepared by nanoprecipitation: Drug loading and release studies of a water soluble drug, J. Controlled Release, 57, 171-185.
100. Bilati, U., Allemann, E., and Doelker, E. (2005), Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles, Eur. J. Pharm. Sci., 24, 67-75.
101. Bilati, U., Allemann, E., and Doelker, E. (2005), Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues, AAPS Pharm. Sci. Tech., 6, 74.
102. Astete, C. E., and Sabliov, C. M. (2006), Synthesis and characterization of PLGA nanoparticles, J. Biomater. Sci. Polym. Ed., 17, 247-289.
103. Zwiorek, K., Kloechner, J., Wagner, E., and Coester, C. (2004), Gelatin nanoparticle as a new and simple gene delivery system, J. Pharm. Pharm. Sci., 7, 22-28.
104. Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., and Farokhzad, O. C. (2007), Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery, Biomaterials, 28, 869-876.
105. Hillery, A. M., and Florence, A. T. (1996), The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat, Int. J. Pharm., 132, 123-130.
106. Peracchia, M. T., Vauthier, C., Puisieux, F., and Couvreur, P. (1997), Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol), J. Biomed. Mater. Res., 34, 317-326.
107. Suk, J. S., Suh, J., Choy, K., Lai, S. K., Fu, J., and Hanes, J. (2006), Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles, Biomaterials, 27, 5143-5150.
108. Aktas, Y., Yemisci, M., Andrieux, K., Gursoy, R. N., Alonso, M. J., FernAndez-Megia, E., Novoa-Carballal, R., Quinoa, E., Riguera, R., Sargon, M. F., Celik, H. H., Demir, A. S., Hincal, A. A., Dalkara, T., Capan, Y., and Couvreur, P. (2005), Development and brain delivery of chitosan-PEG nanoparticles: Functionalized with the monoclonal antibody OX26, Bioconjugate Chem., 16, 1503-1511.
109. Park, J. H., Kwon, S., Nam, J.-O., Park, R.-W., Chung, H., Seo, S. B., Kim, I.-S., Kwon, I. C., and Jeong, S. Y. (2004), Self-assembled nanoparticles based on glycol chitosan bearing 5h-cholanic acid for RGD peptide delivery, J. Controlled Release, 95, 579-588.
110. Klier, J., Tucker, C. J., Kalantar, T. H., and Green, D. P. (2000), Properties and applications of microemulsions, Adv. Mater., 12, 1751-1757.
111. Muller, R. H., Radtke, M., and Wissing, S. A. (2002), Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations, Adv. Drug Deliv. Rev., 54, S131-S155.
112. Goppert, T. M., and Muller, R. H. (2003), Plasma protein adsorption of Tween 80-and Poloxamer 188-stabilized solid lipid nanoparticles, J. Drug Target., 11, 225-231.
113. Wong, H. L., Bendayan, R., Rauth, A. M., and Wu, X. Y. (2006), Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer, J. Controlled Release, 116, 275-284.
114. Hu, F. Q., Hong, Y., and Yuan, H. (2004), Preparation and characterization of solid lipid nanoparticles containing peptide, Int. J. Pharm., 273, 29-35.
115. Garcia-Fuentes, M., Torres, D., and Alonso, M. J. (2002), Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules, Coll. Surf. B Biointerf., 27, 159-168.
116. Brannon-Peppas, L., and Blanchette, J. O. (2004), Nanoparticle and targeted systems for cancer therapy, Adv. Drug Deliv. Rev., 56, 1649-1659.
117. Lockman, P. R., Mumper, R. J., Khan, M. A., and Allen, D. D. (2002), Nanoparticle technology for drug delivery across the blood-brain barrier, Drug Dev. Ind. Pharm., 28, 1-13.
118. Nishioka, Y., and Yoshino, H. (2001), Lymphatic targeting with nanoparticulate system, Adv. Drug Deliv. Rev., 47, 55-64.
119. Csaba, N., Caamano, P., Sanchez, A., Dominguez, F., and Alonso, M. J. (2005), PLGA: Poloxamer and PLGA:Poloxamine blend nanoparticles: New carriers for gene delivery, Biomacromolecules, 6, 271-278.
120. Bagwe, R. P., Kanicky, J. R., Palla, B. J., Patanjali, P. K., and Shah, D. O. (2001), Improved drug delivery using microemulsions: Rationale, recent progress, and new horizons, Crit. Rev. Ther. Drug Carrier Syst., 18, 77-140.
121. Nayak, S., and Lyon, L. A. (2005), Soft nanotechnology with soft nanoparticles, Ang. Chem. Int. Ed., 44, 7686-7708.
122. Tomalia, D. A., Baker, H., Dewald, J. R., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., and Smith, P. (1985), A new class of polymers: Starburst-dendritic macromolecules, Polym. J., 17, 117-132.
123. Tomalia, D. A., Baker, H., Dewald, J. R., Hall, M., Kallos, G., Martin, S., Roeck, J., Ryder, J., and Smith, P. (1986), Dendritic macromolecules: Synthesis of starburst dendrimers, Macromolecules, 19, 2466-2468.
124. Svenson, S., and Tomalia, D. A. (2005), Dendrimers in biomedical applications - Reflections on the field, Adv. Drug Deliv. Rev., 57, 2106-2129.
125. Lacerda, L., Bianco, A., Prato, M., and Kostarelos, K. (2006), Carbon nanotubes as nanomedicines: From toxicology to pharmacology, Adv. Drug Deliv. Rev., 58, 1460-1470.
126. Smart, S. K., Cassady, A. I., Lu, G. Q., and Martin, D. J. (2006), The biocompatibility of carbon nanotubes, Carbon, 44, 1034-1047.
127. Keck, C. M., and Muller, R. H. (2006), Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation, Eur. J. Pharm. Biopharm., 62, 3-16.
128. Guerin, C. B. E., and Szleifer, I. (1999), Self-assembly of model nonionic amphiphilic molecules, Langmuir, 15, 7901-7911.
129. Choi, S. K., Vu, T. K., Jung, J. M., Kim, S. J., Jung, H. R., Chang, T., and Kim, B. H. (2005), Nucleoside-based phospholipids and their liposomes formed in water, ChemBio-Chem, 6, 432-439.
130. Snip, E., Shinkai, S., and Reinhoudt, D. N. (2001), O rganogels of a nucleobase-bearing gelator and the remarkable effects of nucleoside derivatives and a porphyrin derivative on the gel stability, Tetrahedr. Lett., 42, 2153-2156.
131. Engberts, J. B. F. N., and Hoekstra, D. (1995), Vesicle-forming synthetic amphiphiles, Biochim. Biophys. Acta, 1241, 323-340.
132. Giulieri, F., and Krafft, M. P. (2003), Tubular microstructures made from nonchiral single-chain fluorinated amphiphiles: Impact of the structure of the hydrophobic chain on the rolling-up of bilayer membrane, J. Coll. Interf. Sci., 258, 335-344.
133. Giorgi, T., Lena, S., Mariani, P., Cremonini, M. A., Masiero, S., Pieraccini, S., Rabe, J. P., Samori, P., Spada, G. P., and Gottarelli, G. (2003), Supramolecular helices via self-assembly of 8-oxoguanosines, J. Am. Chem. Soc., 125, 14741-14749.
134. Yanagawa, H., Ogawa, Y., Furuta, H., and Tsuno, K. (1989), Spontaneous formation of superhelical strands, J. Am. Chem. Soc., 111, 4567-4570.
135. Zemel, A., Fattal, D. R., and Ben-Shaul, A. (2003), Energetics and self-assembly of amphipathic peptide pores in lipid membranes, Biophys. J., 84, 2242-2255.
136. Chabaud, P., Camplo, M., Payet, D., Serin, G., Moreau, L., Barthelemy, P., and Grinstaff, M. W. (2006), Cationic nucleoside lipids for gene delivery, Bioconjugate Chem., 17, 466-472.
137. Vaizoglu, M. O., and Speiser, P. P. (1986), Pharmacosomes - A novel drug delivery system, Acta Pharm. Suec., 23, 163-172.
138. Schreier, S., Malheiros S. V. P., and de Paula, E. (2000), Surface active drugs: Self-association and interaction with membranes and surfactants. Physicochemical and biological aspects, Biochim. Biophys. Acta, 1508, 210-234.
139. Israelachvili, J. N. (1992), I ntermolecular and Surface Forces with Applications to Colloidal and Biological Systems, Academic, London.
140. Jin, Y., Li, M., Tong, L., Wang, L., and Peng, T. (2003), Lipid derivatives of nucleoside analogues and their salts, China Patent CN1259331.
141. Jin, Y., and Ai, P. (2004), Cholesteryl derivatives of nucleoside analogues, China Patent CN1566130.
142. Jin, Y., Du, L., Xing, L., and Xin, R. (2006), Cholesteryl phosphoryl derivatives of nucleoside analogues, China Patent Application 2006101122957.
143. Jin, Y., Qiao, Y., and Hou, X. (2006), The effects of chain number and state of lipid derivatives of nucleosides on hydrogen bonding and self-assembly through the investigation of Langmuir-Blodgett films, Appl. Surf. Sci., 252, 7926-7929.
144. Jin, Y. (2007), Effect of temperature on the state of the self-assembled nanoparticles prepared from an amphiphilic lipid derivative of acyclovir, Coll. Surf. B Biointerf., 54, 124-125.
145. Aquaro, S., Calio, R., Balzarini, J., Bellocchi, M. C., Garaci, E., and Perno, C. F. (2002), Macrophages and HIV infection: Therapeutical approaches toward this strategic virus reservoir, Antivir. Res., 55, 209-225.
146. European Science Foundation (2005), Nanomedicine, An ESF-European Medical Research Council (EMRC) forward look report, European Science Foundation, Strasbourg.
147. Wagner, V., Dullaart, A., Bock, A.-K., and Zweck, A. (2006), The emerging nanomedicine landscape, Nat. Biotechnol., 24, 1211-1217.